Gaucher Disease Treatment Market
Global Gaucher Disease Treatment Market Size, Share & Trends Analysis Report by Disease Type (Type I, Type II, and Type III),By Treatment Type (Enzyme Replacement Therapy (ERT), and Substrate Reduction Treatment (SBT)), and Forecast 2019-2025 Update Available - Forecast 2024-2030
The global Gaucher disease treatment market is anticipated to grow at a considerable CAGR of around 3% during the forecast period. Gaucher disease is a type of genetic disease caused by mutation of cells that leads to one of the enzymes in the body not working properly. The body constantly recycles itself as old cells die and new cells are made There is a long list of enzymes that are responsible for the recycling dead cells, one of which when it's not working properly leads to Gaucher disease. Gaucher disease has a lot of different symptoms out of which the most common is an enlarged liver and spleen. Currently, quite a lot of research is going on in the field regarding the treatment of Gaucher disease, which in turn, fueling the growth of the Gaucher disease treatment market.
However, the SBT causes any adverse reaction in patients ranging from weight loss, tremor, flatulence, abdominal pain, dyspepsia, paresthesia, influenza-like symptoms, visual disturbances, and thrombocytopenia which is lowering the popularity of SBT in the Gaucher disease market. In addition, the high cost associated with the treatment is limiting the growth of the global Gaucher disease treatment market. For instance, according to the National Institute of Health in 2018, the average wholesale prices of ERTs are $1,903 per vial for imiglucerase (400 units), $1,652 per vial for velaglucerase (400 units), and $935 per vial for taliglucerase (200 units). Patients are often administered 60 units/kg every two weeks. As this dosage, the approximate annual costs for imiglucerase, velaglucerase, and taliglucerase would be $544,260, $472,475, and $510,510, respectively.
Segmental Outlook
The global Gaucher disease treatment market is segmented on the basis of disease type and treatment type. Based on disease type, the market is sub-segmented into type I, type II, and Type III. Based on the treatment type, the market is sub-segmented into Enzyme Replacement Therapy (ERT) and Substrate Reduction Treatment (SBT).
Global Gaucher Disease Market Share by Disease Type, 2018 (%)
Disease Type Insights: Type I Gaucher Disease to Hold a Significant Share in the Market
Type I Gaucher disease segment is anticipated to hold a significant share in the Gaucher disease market owing to the increasing number of cases across the globe. The short-term management goals of Type I includes anemia-related symptoms, bleeding tendency, visceral complications, and general well-being. In addition to this, managing pulmonary complications falls into the long-term goals to treat the Type I. Factors such as proper education of the patient and family about the disease and therapy would help to manage the Type I Gaucher disease effectively. Additionally, early detection of signs and symptoms indicative of GD3, such as eye movement abnormalities with Other associated conditions Including iron deficiency anemia, serum vitamin D, cholelithiasis, cholecystitis is also aid in managing the Type I disease.
Regional Outlooks
The global Gaucher disease treatment market is further segmented on the basis of geography into North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to hold a prominent market share in the Gaucher disease treatment market during the forecast period owing to the increasing number of patients diagnosed with Gaucher disease in the region. According to the National Organization for Rare Disease in 2017, approximately 6,000 individuals are living with Gaucher disease alone in the US.
Global Gaucher Disease Market Growth by Region, 2019-2025
Market Players Outlook
Some of the key players operating in the global Gaucher disease treatment market include Pfizer Inc., Johnson and Johnson, Amicus Therapeutics, ERAD Therapeutics Inc., Genzyme Corp. (Sanofi), Takeda Pharmaceuticals Co. Ltd., JCR Pharmaceuticals Co., Ltd., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, mergers and acquisitions, collaborations with government, and others to stay competitive in the market. For instance, in March 2018, FDA approved Elelyso (taliglucerase alfa) that can be used for long-term enzyme replacement therapy to treat a form of Gaucher disease, which is a rare genetic disorder. Elelyso comes in the form of an injection that intends to replace the missing enzyme in patients with a confirmed diagnosis of Type 1 (non-neuropathic) Gaucher disease.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Gaucher disease treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Genzyme Corp. (Sanofi Company)
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Johnson & Johnson (Actelion Pharmaceuticals Ltd.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Pfizer Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Protalix BioTherapeutics
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Gaucher Disease Treatment Market by Disease Type
5.1.1. Type I
5.1.2. Type II
5.1.3. Type III
5.2. Gaucher Disease Treatment Market by Treatment Type
5.2.1. Enzyme Replacement Therapy (ERT)
5.2.2. Substrate Reduction Treatment (SBT)
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AVROBIO, Inc.
7.2. Amicus Therapeutics
7.3. CENTOGENE N.V.
7.4. ERAD Therapeutics Inc.
7.5. Genzyme Corp. (Sanofi Company)
7.6. Greenovation Biotech GmbH
7.7. JCR Pharmaceuticals Co., Ltd.
7.8. Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
7.9. Lixte Biotechnology Holdings, Inc.
7.10. Novartis International AG
7.11. ORPHAZYME A/S
7.12. Oxyrane
7.13. Pfizer Inc.
7.14. Protalix BioTherapeutics, Inc.
7.15. Takeda Pharmaceutical Co. Ltd.
1. GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
2. GLOBAL TYPE I GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL TYPE II GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL TYPE III GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
5. GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
6. GLOBAL ENZYME REPLACEMENT THERAPY (ERT) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL SUBSTRATE REDUCTION TREATMENT (SBT)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
8. GLOBAL GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
9. NORTH AMERICAN GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
10. NORTH AMERICAN GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
11. NORTH AMERICAN GAUCHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
12. EUROPEAN GAUCHER TREATMENT DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
13. EUROPEAN GAUCHER TREATMENT DISEASE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
14. EUROPEAN GAUCHER TREATMENT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
15. ASIA-PACIFIC GAUCHER TREATMENT DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
16. ASIA-PACIFIC GAUCHER TREATMENT DISEASE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
17. ASIA-PACIFIC GAUCHER TREATMENT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
18. REST OF THE WORLD GAUCHER TREATMENT DISEASE MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
19. REST OF THE WORLD GAUCHER TREATMENT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
1. GAUCHER TREATMENT DISEASE MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
2. GAUCHER TREATMENT DISEASE MARKET SHARE BY TREATMENT TYPE, 2018 VS 2025 (%)
3. GAUCHER TREATMENT DISEASE MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
4. US GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
5. CANADA GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
6. UK GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
7. FRANCE GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
8. GERMANY GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
9. ITALY GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
10. SPAIN GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
11. ROE GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
12. INDIA GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
13. CHINA GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
14. JAPAN GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
15. REST OF ASIA-PACIFIC GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF THE WORLD GAUCHER TREATMENT DISEASE MARKET SIZE, 2018-2025 ($ MILLION)
